Carasent (CARA.OL) Stock Analysis & AI Equity Report
Carasent (CARA.OL) overview
Carasent (CARA.OL) stock analysis and AI equity research. For the latest completed financial year, 2023, Carasent reported revenue of NOK 244m and operating profit of NOK -77.5m; the year-end share price was 11.06 NOK and market capitalisation was NOK 860m. Carasent is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Carasent's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-12-12. Data will be refreshed during report generation.
About Carasent
Carasent ASA develops and provides mission-critical healthcare software, including cloud-based electronic health record and medical record systems, workflow automation tools, partner integrations, business intelligence, and digital communication services. Its products serve healthcare, rehabilitation, and occupational health providers, helping customers streamline administration, improve data use, and support clinical and operational workflows.
Generate the Carasent report
Carasent is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Carasent and represent the latest completed financial year (2023). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.